Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Synairgen SG016, 2020
RCTSNG001 inhaled interferon betaplaceboCOVID 19 hospitalizedhigh
50/51 suggested
  • suggested 1.3-fold increase in clinical improvement but with a low degree of certainty due to high risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).